不同剂量、用法的吉西他滨联合伯尔定治疗晚期非小细胞肺癌比较  

Gemcitabine of different dosages and methods plus Carboplatin in the treatment of patients with advanced non-small cell lung canar.

作　　者：姚文秀[1] 邹立群[1] 彭枫[1] 魏阳[2] 

机构地区：[1]四川大学华西医院,四川成都610041 [2]四川省肿瘤医院内科

出　　处：《四川医学》2006年第3期269-270,共2页Sichuan Medical Journal

摘　　要：目的 观察不同剂量、用法的吉西他滨联合伯尔定治疗晚期非小细胞肺癌的疗效和不良反应。方法 将66例经病理或细胞学证实的晚期非小细胞肺癌患者分为A、B两组。A组：吉西他滨800～1000mg/m^2，静脉滴注，第1,8,15天，伯尔定AUC=5～6，静脉滴注，第1天，28d为1周期；B组：吉西他滨1100～1200mg／m^2，静脉滴注，第1，8天，伯尔定用法同前，21d为1周期，连用至少2个周期方可评价疗效。结果 A、B两组有效率（CR＋PR）分别为44．1％和41．2％（P〉0.05）；中位痰病进展时间分别为6，5个月和6．2个月（P〉0．05）；两组消化道反应相似，白细胞下降B组较A组明显，但P〉0．05，无统计学意义，血小板减少B组也较A组显著，P〈0．05，差异有统计学意义。结论 两组患者耐受性良好，均能完成治疗，对年老体弱患者和有凝血功能障碍者建议使用A组方案。Objective To observe the efficacy and toxicity of gemcitabine of different dosages and methods plus carboplatin in patients with advanced non-small-cell lung cancer（NSCLC） .Methods 66 patients diagnosed as advanced NSCLC by histology and cytology were divided into A and B group. A group： gemcitabine 800～ 1000mg/m^2, infusion, days 1,8 and 15 plus carboplatin AUC = 5 ～ 6, day 1. Cycles were repeated every 28 days. B group ：gemcitabine 1100- 1200mg/m^2, infusion, days 1 and 8 plus carboplatin AUC = 5 - 6, day 1, Cycles were repeated every 21 days. Results The objective response rates of these two group were respectively 44.1% and 41.2 %（ P 〉 0.05） ;No significant differences between two groups were observed in median time to progression（6.5 months A group,6.2 months B group）. Gastroenteric reactions of two group were similar. B group had a higher incidence of leukopenia than A group （ P 〉 0.05 ）. So as thrombasthenia （ but P 〈 0.05 ）. Conclusion There two regimens had good tolerances. To oMcr patients and patients with thrombastheraia, we recommended they put to use the A regimen.

关 键 词：晚期非小细胞肺癌 吉西他滨 伯尔定 

分 类 号：R734.2[医药卫生—肿瘤]